Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced that Co-CEO Chirag Patel will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 AM ET. The event will be accessible via a live webcast through the Company’s Investor Relations website, with a replay available for 30 days post-event. Amneal is focused on developing, manufacturing, and distributing generic and specialty pharmaceuticals, with a broad product portfolio across various therapeutic areas. The Company's growth strategy includes expanding its offerings, particularly in injectables and biosimilars.

Positive

• Participation in the prestigious J.P. Morgan Healthcare Conference highlights Amneal's industry presence.
• Amneal has a diverse portfolio of approximately 250 products, signaling strong market engagement.

Negative

• None.

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal’s Co-Chief Executive Officer and President, will present at the 40^th Annual J.P. Morgan Healthcare Conference on January 12, 2022 at 11:15 AM Eastern Time. A live webcast of the presentation and subsequent Q&A session will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. A replay of the webcast will be posted shortly after the call and will be available for 30 days following the event.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of approximately 250 products in its Generics business and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty business, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE business, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com.

Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; the Company’s strategy for growth; product development; regulatory approvals; market position and expenditures. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and similar words are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: the impact of the COVID-19 pandemic; the impact of global economic conditions; our ability to successfully develop, license, acquire and commercialize new products on a timely basis; our ability to obtain exclusive marketing rights for our products; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to manage our growth through acquisitions and otherwise; our dependence on the sales of a limited number of products for a substantial portion of our total revenues; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to FDA product approval requirements; risks related to federal regulation of arrangements between manufacturers of branded and generic products; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; the continuing trend of consolidation of certain customer groups; our reliance on certain licenses to proprietary technologies from time to time; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; our dependence on third-party agreements for a portion of our product offerings; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; the significant amount of resources we expend on research and development; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; the impact of severe weather; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005081/en/

Anthony DiMeo

Senior Director, Investor Relations

anthony.dimeo@amneal.com

Source: Amneal Pharmaceuticals, Inc.

FAQ

When will Amneal Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Amneal Pharmaceuticals will present on January 12, 2022, at 11:15 AM ET.

Where can I watch the Amneal Pharmaceuticals presentation?

The presentation can be watched via a live webcast on Amneal's Investor Relations website.

What is the stock symbol for Amneal Pharmaceuticals?

The stock symbol for Amneal Pharmaceuticals is AMRX.

What type of products does Amneal Pharmaceuticals focus on?

Amneal Pharmaceuticals develops and distributes generic and specialty pharmaceuticals.